Positioning of Tezepelumab in Severe Asthma

Miralles-López, J. C; Antolín-Amérigo, D; García-Moguel, I; Domínguez-Ortega, J; Delgado-Romero, J; Quirce, S.
J. investig. allergol. clin. immunol ; 34(1): 1-11, 2024. ilus
Artigo em Inglês | IBECS (Espanha) | ID: ibc-230809

Documentos relacionados

  1. Positioning of Tezepelumab in Severe Asthma.
  2. Baseline type 2 biomarker levels and response to tezepelumab in severe asthma.
  3. [Tezepelumab: a new option for the treatment of severe asthma].
  4. Development of an inhaled anti-TSLP therapy for asthma.
  5. [Tezepelumab (Tezspire®) : new biological treatment of severe asthma].
  6. Overview of recent advancements in asthma management.
  7. In severe, uncontrolled asthma, tezepelumab reduced exacerbations over 1 y regardless of type 2 inflammation level.
  8. Tezepelumab in patients with allergic and eosinophilic asthma.
  9. Investigational thymic stromal lymphopoietin inhibitors for the treatment of asthma: a systematic review.
  10. Anti-IL-5 therapies for asthma.